Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL847347

O=S(=O)([O-])C(F)(F)F.c1ccc(C[S+]2CCCC2)cc1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.40
FAAH O00519 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
ELANE P08246 1/20 0.35
PRTN3 P24158 1/20 0.35
PRSS3 P35030 1/20 0.35
PTPN1 P18031 1/20 0.33
KCNH2 Q12809 6/20 0.33
ACHE P22303 3/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
CA2 P00918 2/20 0.33
CES1 P23141 1/20 0.33
CA1 P00915 1/20 0.32
CA5A P35218 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3834477 0.86 CA1 (0.38) HPGDTSHRCA2CA1
SCHEMBL3725337 0.84 HPGD (0.31) HPGDTSHR
Sulfuric Acid SCHEMBL6341005 0.84 FAAH (0.31) FAAHPRSS1PRSS2ELANEPRTN3
Trifluoromethanesulfonic Acid SCHEMBL3832689 0.81 CA1 (0.40) KCNH2ACHETSHRCA2CA1
Trifluoromethanesulfonic Acid SCHEMBL3835272 0.81 KCNH2 (0.40) KCNH2ACHECA2CA1CA5A
Trifluoromethanesulfonic Acid SCHEMBL12499000 0.80 LMNA (0.38) GPR3ACHECA2CA1
SCHEMBL5974326 0.78 CES2 (0.32) FAAHPRSS1PRSS2ELANEPRTN3
Trifluoromethanesulfonic Acid SCHEMBL3096657 0.76 MAPT (0.37) GPR3PTPN1HPGDCA2CES1
Trifluoromethanesulfonic Acid SCHEMBL36383 0.75 GPR3 (0.43) GPR3PTPN1KCNH2ACHECA2
Trifluoromethanesulfonic Acid SCHEMBL36325 0.73 GPR3 (0.42) GPR3PTPN1KCNH2ACHECA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187868-B1 HYPERBRANCHED DENDRITIC POLYETHER AND PROCESS FOR MANUFACTURE THEREOF PERSTORP AB (SE) 2004-07-07 EP claimed
US-6617418-B1 Thermally initiated cationic ring-opening polymerization of an oxetane having at least one reactive group in addition to the oxetane ether; end groups are hydroxyl PERSTORP AB (SE) 2003-09-09 US claimed
EP-1187868-A1 HYPERBRANCHED DENDRITIC POLYETHER AND PROCESS FOR MANUFACTURE THEREOF PERSTORP AB (SE) 2002-03-20 EP claimed
WO-2000056802-A1 HYPERBRANCHED DENDRITIC POLYETHER AND PROCESS FOR MANUFACTURE THEREOF PERSTORP AB (SE) 2000-09-28 WO claimed
US-9855267-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2018-01-02 US disclosed
US-9765054-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2017-09-19 US disclosed
US-20170042892-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2017-02-16 US disclosed
US-9505736-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2016-11-29 US disclosed
US-20150203468-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2015-07-23 US disclosed
EP-2871955-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2015-05-20 EP disclosed
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation (US) 2014-06-12 US disclosed
WO-2014014900-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2014-01-23 WO disclosed
EP-2432820-A2 TERMINALLY UNSATURATED, OXETANE-BASED MACROMONOMERS, AND METHOD FOR THE PRODUCTION THEREOF BYK-Chemie GmbH (DE) 2012-03-28 EP disclosed
EP-2432819-A2 POLYMERS OBTAINABLE FROM OXETANE BASED MACROMONOMERS, METHOD FOR THE PRODUCTION THEREOF, AND THE USE THEREOF AS ADDITIVES IN COATING AGENTS AND PLASTICS BYK-Chemie GmbH (DE) 2012-03-28 EP disclosed
WO-2010133289-A2 TERMINALLY UNSATURATED, OXETANE-BASED MACROMONOMERS, AND METHOD FOR THE PRODUCTION THEREOF BYK-CHEMIE GMBH (DE) 2010-11-25 WO disclosed
WO-2010133288-A2 POLYMERS OBTAINABLE FROM OXETANE BASED MACROMONOMERS, METHOD FOR THE PRODUCTION THEREOF, AND THE USE THEREOF AS ADDITIVES IN COATING AGENTS AND PLASTICS BYK-CHEMIE GMBH (DE) 2010-11-25 WO disclosed
EP-1187868-B1 HYPERBRANCHED DENDRITIC POLYETHER AND PROCESS FOR MANUFACTURE THEREOF PERSTORP AB (SE) 2004-07-07 EP disclosed
US-6617418-B1 Thermally initiated cationic ring-opening polymerization of an oxetane having at least one reactive group in addition to the oxetane ether; end groups are hydroxyl PERSTORP AB (SE) 2003-09-09 US disclosed
EP-1187868-A1 HYPERBRANCHED DENDRITIC POLYETHER AND PROCESS FOR MANUFACTURE THEREOF PERSTORP AB (SE) 2002-03-20 EP disclosed
WO-2000056802-A1 HYPERBRANCHED DENDRITIC POLYETHER AND PROCESS FOR MANUFACTURE THEREOF PERSTORP AB (SE) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF HDAC1, HDAC7, HDAC5 GPR3 4833/4885FAAH 1389/4885PRSS1 863/4885
US-20170042892-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF HDAC1, HDAC7, HDAC5 GPR3 4833/4885FAAH 1389/4885PRSS1 863/4885
US-20150203468-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF HDAC1, HDAC7, HDAC5 GPR3 4833/4885FAAH 1389/4885PRSS1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.